Assessment of anti-HIV-1 antibodies in oral and nasal compartments of volunteers from three different populations
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
In this study, we assessed the feasibility of collecting standardized nasal and salivary samples at centers in Nairobi (Kenya), Kigali (Rwanda) and London (UK) using different collection devices and media (Synthetic absorptive matrices versus flocked swabs, and Salimetrics Oral swabs versus whole oral fluid collection). We detected anti Gag (p24) and envelope (gp140) antibodies in both nasal fluid and salivary collections from all HIV-infected individuals, and cross-reactive anti-p24 antibodies were detected in 10% of HIV-uninfected individuals enrolled at one site. Collections from the nasal turbinates were comparable to samples collected deeper in the nasopharyngeal tract, and the yield of anti-p24 IgA in the whole oral fluid samples was higher than in samples collected from the parotid gland. We noted a trend toward reduced levels of anti-HIV antibody in the volunteers receiving anti-retroviral therapy (ART). Levels of antibodies were stable over multiple collection visits. Overall, this study shows that nasal and salivary samples can be collected in a standardized manner over repeated visits in both low and high resource settings. These methods may be used in support of future HIV vaccine clinical trials.
Date Issued
2016-10-01
Date Acceptance
2016-05-05
Citation
JAIDS - Journal of Acquired Immune Deficiency Syndromes, 2016, 73 (2), pp.130-137
ISSN
1525-4135
Publisher
Lippincott, Williams & Wilkins
Start Page
130
End Page
137
Journal / Book Title
JAIDS - Journal of Acquired Immune Deficiency Syndromes
Volume
73
Issue
2
Copyright Statement
© 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an
open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial License 4.0 (CCBY-NC), where it is
permissible to download, share, remix, transform, and buildup the work
provided it is properly cited. The work cannot be used commercially.
open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial License 4.0 (CCBY-NC), where it is
permissible to download, share, remix, transform, and buildup the work
provided it is properly cited. The work cannot be used commercially.
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
Infectious Diseases
mucosal
HIV
vaccine
nasal
salivary
antibody
TEST-OF-CONCEPT
HIV-1 VACCINE
EFFICACY TRIAL
DOUBLE-BLIND
MUCOSAL
VIRUS
CHALLENGE
INFECTION
RESPONSES
REGIONS
Virology
1103 Clinical Sciences
Publication Status
Published